• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

IDARUBICIN Drug Record

  • Summary
  • Interactions
  • Claims
  • IDARUBICIN chembl:CHEMBL1117 ApprovedAntineoplasticImmunotherapy

    Alternate Names:

    IDARUBICIN
    IDAMYCIN
    IMI-30
    (1S,3S)-3-ACETYL-3,5,12-TRIHYDROXY-6,11-DIOXO-1,2,3,4,6,11-HEXAHYDRONAPHTHACEN-1-YL 3-AMINO-2,3,6-TRIDEOXY-ALPHA-L-LYXO-HEXOPYRANOSIDE
    4-DEMETHOXYDAUNOMYCIN
    4-DEMETHOXYDAUNORUBICIN
    5,12-NAPHTHACENEDIONE, 9-ACETYL-7-((3-AMINO-2,3,6-TRIDEOXY-ALPHA-L-LYXO-HEXOPYRANOSYL)OXY)-7,8,9,10-TETRAHYDRO-6,9,11-TRIHYDROXY-, (7S-CIS)-
    IDAMYCIN®
    ZAVEDOS®
    IDARUBICINA
    IDARUBICINE
    IDARUBICINUM
    pubchem.compound:42890
    chemidplus:58957-92-9
    rxcui:5650
    drugbank:01177
    chembl:CHEMBL1117

    Drug Info:

    Drug Class antineoplastic agents
    Year of Approval 1990
    FDA Approval 1990
    Drug Class small molecule
    Drug Indications Antineoplastic Agents
    (5 More Sources)

    Publications:

    Shi JY et al., 2004, Association between single nucleotide polymorphisms in deoxycytidine kinase and treatment response among acute myeloid leukaemia patients., Pharmacogenetics
    LaRochelle et al., 2011, Do AML patients with DNMT3A exon 23 mutations benefit from idarubicin as compared to daunorubicin? A single center experience., Oncotarget
    Iacobucci I et al., 2013, Profiling of drug-metabolizing enzymes/transporters in CD33+ acute myeloid leukemia patients treated with Gemtuzumab-Ozogamicin and Fludarabine, Cytarabine and Idarubicin., Pharmacogenomics J
    He H et al., 2015, Association of ABCB1 polymorphisms with prognostic outcomes of anthracycline and cytarabine in Chinese patients with acute myeloid leukemia., Eur J Clin Pharmacol
    Megías-Vericat JE et al., 2015, Influence of ABCB1 polymorphisms upon the effectiveness of standard treatment for acute myeloid leukemia: a systematic review and meta-analysis of observational studies., Pharmacogenomics J
    Gréen H et al., 2012, Association of ABCB1 polymorphisms with survival and in vitro cytotoxicty in de novo acute myeloid leukemia with normal karyotype., Pharmacogenomics J
    Kim DH et al., 2006, Multidrug resistance-1 gene polymorphisms associated with treatment outcomes in de novo acute myeloid leukemia., Int J Cancer
    Zhou et al., 1999, Topoisomerase II-mediated alterations of K562 drug resistant sublines., Med. Oncol.
    Willmore et al., 2002, Formation and longevity of idarubicin-induced DNA topoisomerase II cleavable complexes in K562 human leukaemia cells., Biochem. Pharmacol.
    De Renzo et al., 1999, Acute promyelocytic leukemia after treatment for non-Hodgkin's lymphoma with drugs targeting topoisomerase II., Am. J. Hematol.
    Bigioni et al., 1994, Base mutation analysis of topoisomerase II-idarubicin-DNA ternary complex formation. Evidence for enzyme subunit cooperativity in DNA cleavage., Nucleic Acids Res.
    Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
    González-Cid et al., 2002, Correlation between chromosome damage and apoptosis induced by fludarabine and idarubicin in normal human lymphocytes., Toxicology
    Megías-Vericat JE et al., 2018, Impact of NADPH oxidase functional polymorphisms in acute myeloid leukemia induction chemotherapy., Pharmacogenomics J
    Reichwagen A et al., 2015, Association of NADPH oxidase polymorphisms with anthracycline-induced cardiotoxicity in the RICOVER-60 trial of patients with aggressive CD20(+) B-cell lymphoma., Pharmacogenomics
    Rossi D et al., 2009, Analysis of the host pharmacogenetic background for prediction of outcome and toxicity in diffuse large B-cell lymphoma treated with R-CHOP21., Leukemia
    Wojnowski L et al., 2005, NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity., Circulation
    Serie DJ et al., 2017, Genome-wide association study of cardiotoxicity in the NCCTG N9831 (Alliance) adjuvant trastuzumab trial., Pharmacogenet Genomics
    Hertz DL et al., 2016, Evidence for association of SNPs in ABCB1 and CBR3, but not RAC2, NCF4, SLC28A3 or TOP2B, with chronic cardiotoxicity in a cohort of breast cancer patients treated with anthracyclines., Pharmacogenomics
    Majsterek et al., 2003, TEL-fusion oncogenic tyrosine kinases determine leukemic cells response to idarubicin., Anticancer Drugs
    Cheong HS et al., 2014, NT5C3 polymorphisms and outcome of first induction chemotherapy in acute myeloid leukemia., Pharmacogenet Genomics
    Harousseau et al., 1996, Treatment of acute myeloblastic leukemia in adults. The GOELAM experience., Hematol Cell Ther
  • IDARUBICIN   NCF4

    Interaction Score: 5.15

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    28763429 28485375 26799497 19448608 16330681


    Sources:
    PharmGKB

  • IDARUBICIN   CYBA

    Interaction Score: 2.86

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    28485375 25823784 19448608 16330681


    Sources:
    PharmGKB

  • IDARUBICIN   RAC2

    Interaction Score: 1.72

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    28485375


    Sources:
    PharmGKB

  • IDARUBICIN   NT5C3A

    Interaction Score: 1.14

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25000516


    Sources:
    PharmGKB

  • IDARUBICIN   SULT2B1

    Interaction Score: 1.14

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22584460


    Sources:
    PharmGKB

  • IDARUBICIN   DNMT3A

    Interaction Score: 0.86

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22081665


    Sources:
    CIViC

  • IDARUBICIN   SLC22A12

    Interaction Score: 0.49

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22584460


    Sources:
    PharmGKB

  • IDARUBICIN   DCK

    Interaction Score: 0.31

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15564883


    Sources:
    PharmGKB

  • IDARUBICIN   ETV6

    Interaction Score: 0.29

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    14501384


    Sources:
    NCI

  • IDARUBICIN   TOP2A

    Interaction Score: 0.17

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name -
    Novel drug target Established target

    PMIDs:
    10523799 12034365 10203104 8036155 11752352 11836027


    Sources:
    TdgClinicalTrial TEND

  • IDARUBICIN   CYP2E1

    Interaction Score: 0.15

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22584460


    Sources:
    PharmGKB

  • IDARUBICIN   CSF2

    Interaction Score: 0.08

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    8915668


    Sources:
    NCI

  • IDARUBICIN   SLCO1B1

    Interaction Score: 0.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22584460


    Sources:
    PharmGKB

  • IDARUBICIN   TOP2B

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TTD

  • IDARUBICIN   ABCB1

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25567217 25558979 20938465 16331627


    Sources:
    PharmGKB

  • IDARUBICIN   FLT3

    Interaction Score: 0.02

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:

    PMIDs:
    None found


    Sources:
    MyCancerGenomeClinicalTrial

  • IDARUBICIN   THRB

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • IDARUBICIN   BLM

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • IDARUBICIN   MPHOSPH8

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • IDARUBICIN   MTOR

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • IDARUBICIN   DRD1

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • IDARUBICIN   RECQL

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • IDARUBICIN   POLH

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • IDARUBICIN   APEX1

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • IDARUBICIN   POLB

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • IDARUBICIN   CBX1

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • IDARUBICIN   HTT

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • IDARUBICIN   FEN1

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • IDARUBICIN   USP1

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • IDARUBICIN   POLI

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • IDARUBICIN   ATXN2

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • IDARUBICIN   POLK

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • IDARUBICIN   ATAD5

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • IDARUBICIN   KCNH2

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • IDARUBICIN   MAPT

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • IDARUBICIN   EHMT2

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • TEND: IDARUBICIN

    • Version: 01-August-2011

    Alternate Names:
    IDARUBICIN Primary Drug Name

    Drug Info:
    Year of Approval 1990
    Drug Class antineoplastic agents

    Publications:

  • TdgClinicalTrial: IDARUBICIN

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications Antineoplastic Agents
    Drug Class small molecule
    FDA Approval 1990

    Publications:

  • NCI: IDARUBICIN

    • Version: 14-September-2017

    Alternate Names:
    C562 NCI drug code

    Drug Info:

    Publications:
    Majsterek et al., 2003, TEL-fusion oncogenic tyrosine kinases determine leukemic cells response to idarubicin., Anticancer Drugs
    Harousseau et al., 1996, Treatment of acute myeloblastic leukemia in adults. The GOELAM experience., Hematol Cell Ther

  • PharmGKB: idarubicin

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Iacobucci I et al., 2013, Profiling of drug-metabolizing enzymes/transporters in CD33+ acute myeloid leukemia patients treated with Gemtuzumab-Ozogamicin and Fludarabine, Cytarabine and Idarubicin., Pharmacogenomics J
    Megías-Vericat JE et al., 2015, Influence of ABCB1 polymorphisms upon the effectiveness of standard treatment for acute myeloid leukemia: a systematic review and meta-analysis of observational studies., Pharmacogenomics J
    Gréen H et al., 2012, Association of ABCB1 polymorphisms with survival and in vitro cytotoxicty in de novo acute myeloid leukemia with normal karyotype., Pharmacogenomics J

  • CIViC: IDARUBICIN

    • Version: 14-September-2020

    Alternate Names:

    Drug Info:

    Publications:
    LaRochelle et al., 2011, Do AML patients with DNMT3A exon 23 mutations benefit from idarubicin as compared to daunorubicin? A single center experience., Oncotarget

  • DTC: IDARUBICIN

    • Version: 02-September-2020

    Alternate Names:
    CHEMBL1117 ChEMBL Drug ID

    Drug Info:

    Publications:

  • TTD: Idarubicin

    • Version: 2020.06.01

    Alternate Names:
    D01XDL TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL1117

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

  • MyCancerGenomeClinicalTrial: IDARUBICINE

    • Version: 30-February-2014

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21